Diabetes

In recent years, GLP‑1-based treatments for obesity have evolved from being primarily a diabetes-focused strategy to becoming a powerful tool for managing weight and reducing cardiometabolic risk—especially in individuals without type 2 diabetes. This growing trend is shifting how clinicians identify and manage obesity, moving beyond A1C levels to a …

Could a diabetes medication help women with PCOS regain control of their cycles and metabolism? GLP‑1 receptor agonists, best known for treating type 2 diabetes and obesity, are showing promise for women with polycystic ovary syndrome (PCOS). These medications may support weight loss, improve insulin resistance, and even lead to …

Diabetic ketoacidosis (DKA) continues to be one of the most dangerous acute complications faced by people with diabetes, particularly those on insulin or SGLT2 inhibitors. While traditional approaches rely on intermittent blood ketone checks, a new frontier is emerging—continuous ketone monitoring for DKA prevention. This article explores how this technology …

As GLP‑1 therapies expand into pediatric care, a growing number of providers are asking how to best implement them in adolescents diagnosed with both type 2 diabetes and obesity. The conversation around GLP‑1 therapy for adolescents with type 2 diabetes is evolving quickly. With promising clinical results, these therapies bring …

The GLP‑1 GIP co‑agonist pipeline is ushering in a new era of metabolic therapy that could reshape the way clinicians approach type 2 diabetes and obesity management. As drug developers push beyond single-pathway therapies like GLP‑1 receptor agonists, new combinations—such as GLP‑1/GIP dual agonists and triple agonists—are showing potential to …

AI decision support in diabetes care is reshaping how clinicians manage continuous glucose monitoring (CGM) and insulin dosing. These tools deliver quick data-driven recommendations, raising key questions: How do we preserve clinical judgment? Where does AI end and provider expertise begin? This article explains how to safely evaluate and use …

Many patients on GLP‑1 therapy describe their cravings as quieter, their urges to snack reduced, and their minds less consumed by food. This shift, often described as a reduction in “food noise,” reflects significant physiological changes triggered by GLP‑1 medications. As more clinicians prescribe these therapies, it’s vital to understand …

In clinical practice, patients with both type 2 diabetes and heart failure with preserved ejection fraction (HFpEF) often present with overlapping symptoms and complex care needs. The evolving landscape of cardiometabolic treatment has brought new attention to GLP‑1 HFpEF diabetes management, especially as recent evidence suggests that glucagon-like peptide‑1 receptor …

The arrival of oral GLP‑1 therapy for type 2 diabetes marks a pivotal shift in diabetes care. Traditionally available only as injections, GLP‑1 receptor agonists have shown impressive results in lowering blood glucose, aiding in weight loss, and protecting the heart. Now, oral versions like semaglutide are removing barriers for …

With the release of the ADA 2026 diabetes sleep guidelines, the American Diabetes Association has officially elevated sleep and circadian rhythm health to core pillars of diabetes care—right alongside nutrition, physical activity, and medication. These new standards mark a significant shift toward more holistic and behavioral-focused approaches to managing diabetes. …